Tumor Necrosis Factor Blocker [EPC]

806700 reported adverse events

Drugs of this class: INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	94496
1	INJECTION SITE PAIN	57665
2	ARTHRALGIA	53101
3	PAIN	48175
4	RHEUMATOID ARTHRITIS	47201
5	OFF LABEL USE	46405
6	INJECTION SITE ERYTHEMA	41500
7	FATIGUE	36004
8	CONDITION AGGRAVATED	29736
9	HEADACHE	29301

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	287	0.9762
1	INJECTION SITE RECALL REACTION	482	0.9737
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	3174	0.9418
3	SWOLLEN JOINT COUNT INCREASED	680	0.9067
4	RHEUMATOID FACTOR POSITIVE	2705	0.8808
5	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1639	0.8384
6	RHEUMATIC FEVER	872	0.8119
7	PEMPHIGUS	5646	0.8016
8	C-REACTIVE PROTEIN ABNORMAL	2720	0.7774
9	HAND DEFORMITY	5774	0.7270

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]